Prime editors, which utilize a Cas9-nickase fused to a reverse transcriptase and a pegRNA, require a multi-faceted analytical approach. Documentation for an IND filing must rigorously characterize the integrity and purity of the pegRNA, the expression and activity of the fusion protein, and definitively quantify editing efficiency while assessing any potential guide-dependent non-target events.

We develop and qualify all analytical methods in a phase-appropriate manner. This process involves establishing method specificity, accuracy, precision, and robustness. All documentation is generated within GxP-compliant environments, ensuring the data package is suitable for direct inclusion in regulatory submissions to agencies like the FDA.

Yes. Our analytical services are modality-agnostic, covering both viral vectors (such as AAV or adenovirus) and non-viral delivery systems like lipid nanoparticles (LNPs) used to deliver prime editor components. We tailor the analytical package to the specific delivery vehicle and its associated impurities and stability profile.

The precision of prime editors offers a significant advantage by avoiding the double-stranded DNA breaks associated with earlier nuclease platforms. This mechanism, however, introduces distinct requirements for the analytical data package supporting an IND application. Regulators require a clear, data-driven narrative that confirms not just on-target editing efficiency but also the purity, identity, and consistency of the multi-component therapeutic.

A successful regulatory submission depends on a suite of well-qualified assays. Key characterization includes:

* **pegRNA Integrity and Purity**: Analysis to confirm the full-length prime editing guide RNA sequence and identify any truncations or impurities from the manufacturing process.

* **Fusion Protein Characterization**: Assays to verify the identity, concentration, and enzymatic activity of the Cas9-reverse transcriptase fusion protein.

* **Potency and Editing Efficiency**: Validated cell-based assays to quantify the precise level of desired edits and screen for unintended insertions or deletions (indels).

* **Guide-Dependent Non-Target Analysis**: Rigorous assessment of potential non-target editing events at sites predicted by computational analysis.

The strategic value of a robust preclinical data package is a consistent principle across next-generation therapeutics. For instance, preclinical evaluation of vector platforms in nonhuman primate models has demonstrated that a well-characterized system can produce predictable and favorable biological outcomes, such as reduced viral DNA in tissues (PMID: 33658998). This same principle applies to prime editor analytics: a comprehensive characterization package provides regulators with the confidence that the therapeutic’s behavior is understood and controlled.

Our scientific team operates within a >100,000 sq ft facility designed for these complex analytical and preclinical programs `

`. While Franklin Biolabs was formally launched in 2024, our core scientific leadership and principal scientists have maintained a 100% successful IND rate since 2019, providing sponsors with an unmatched level of experience.

This deep expertise in analytical development is a core component of our [Vector | CMC | Analytics Services](/vector-cmc-analytics-services_7.md), ensuring your prime editor program is built on a solid regulatory foundation.

***